Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials
Lymphocyte-activation gene 3 (LAG-3) has emerged as a key immune checkpoint regulating immune responses in the context of cancer. The inhibitory effect of LAG-3-expressing T cells contributes to suppressing anti-tumor immunity and promoting tumor progression. This review discusses the function of LA...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1501613/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850160401608605696 |
|---|---|
| author | Ke Ren Hayam Hamdy Abdo Meyiah Eyad Elkord Eyad Elkord Eyad Elkord |
| author_facet | Ke Ren Hayam Hamdy Abdo Meyiah Eyad Elkord Eyad Elkord Eyad Elkord |
| author_sort | Ke Ren |
| collection | DOAJ |
| description | Lymphocyte-activation gene 3 (LAG-3) has emerged as a key immune checkpoint regulating immune responses in the context of cancer. The inhibitory effect of LAG-3-expressing T cells contributes to suppressing anti-tumor immunity and promoting tumor progression. This review discusses the function of LAG-3 in immune suppression, its interactions with ligands, and its potential as a prognostic biomarker for cancers. We also explore therapeutic strategies targeting LAG-3, including monoclonal antibodies, small molecule inhibitors, and CAR T cells. This review summarizes the current preclinical and clinical studies on LAG-3, highlighting the potential of therapeutic regimens targeting LAG-3 to enhance antitumor immunity and improve patients’ outcomes. Further studies are needed to fully elucidate the mechanism of action of LAG-3 and optimize its application in tumor therapy. |
| format | Article |
| id | doaj-art-2348de7bc60e45f485e3708e8ddee7af |
| institution | OA Journals |
| issn | 1664-3224 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-2348de7bc60e45f485e3708e8ddee7af2025-08-20T02:23:09ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-11-011510.3389/fimmu.2024.15016131501613Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentialsKe Ren0Hayam Hamdy1Abdo Meyiah2Eyad Elkord3Eyad Elkord4Eyad Elkord5Department of Biosciences and Bioinformatics, School of Science, Suzhou Municipal Key Lab in Biomedical Sciences and Translational Immunology, Xi’an Jiaotong-Liverpool University, Suzhou, Jiangsu, ChinaDepartment of Forensic Medicine and Toxicology, Faculty of Veterinary Medicine, New Valley University, New Valley, EgyptDepartment of Biosciences and Bioinformatics, School of Science, Suzhou Municipal Key Lab in Biomedical Sciences and Translational Immunology, Xi’an Jiaotong-Liverpool University, Suzhou, Jiangsu, ChinaDepartment of Biosciences and Bioinformatics, School of Science, Suzhou Municipal Key Lab in Biomedical Sciences and Translational Immunology, Xi’an Jiaotong-Liverpool University, Suzhou, Jiangsu, ChinaCollege of Health Sciences, Abu Dhabi University, Abu Dhabi, United Arab EmiratesBiomedical Research Center, School of Science, Engineering and Environment, University of Salford, Manchester, United KingdomLymphocyte-activation gene 3 (LAG-3) has emerged as a key immune checkpoint regulating immune responses in the context of cancer. The inhibitory effect of LAG-3-expressing T cells contributes to suppressing anti-tumor immunity and promoting tumor progression. This review discusses the function of LAG-3 in immune suppression, its interactions with ligands, and its potential as a prognostic biomarker for cancers. We also explore therapeutic strategies targeting LAG-3, including monoclonal antibodies, small molecule inhibitors, and CAR T cells. This review summarizes the current preclinical and clinical studies on LAG-3, highlighting the potential of therapeutic regimens targeting LAG-3 to enhance antitumor immunity and improve patients’ outcomes. Further studies are needed to fully elucidate the mechanism of action of LAG-3 and optimize its application in tumor therapy.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1501613/fullbiomarkerT cellsLAG-3immune checkpointcancer |
| spellingShingle | Ke Ren Hayam Hamdy Abdo Meyiah Eyad Elkord Eyad Elkord Eyad Elkord Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials Frontiers in Immunology biomarker T cells LAG-3 immune checkpoint cancer |
| title | Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials |
| title_full | Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials |
| title_fullStr | Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials |
| title_full_unstemmed | Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials |
| title_short | Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials |
| title_sort | lymphocyte activation gene 3 in cancer immunotherapy function prognostic biomarker and therapeutic potentials |
| topic | biomarker T cells LAG-3 immune checkpoint cancer |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1501613/full |
| work_keys_str_mv | AT keren lymphocyteactivationgene3incancerimmunotherapyfunctionprognosticbiomarkerandtherapeuticpotentials AT hayamhamdy lymphocyteactivationgene3incancerimmunotherapyfunctionprognosticbiomarkerandtherapeuticpotentials AT abdomeyiah lymphocyteactivationgene3incancerimmunotherapyfunctionprognosticbiomarkerandtherapeuticpotentials AT eyadelkord lymphocyteactivationgene3incancerimmunotherapyfunctionprognosticbiomarkerandtherapeuticpotentials AT eyadelkord lymphocyteactivationgene3incancerimmunotherapyfunctionprognosticbiomarkerandtherapeuticpotentials AT eyadelkord lymphocyteactivationgene3incancerimmunotherapyfunctionprognosticbiomarkerandtherapeuticpotentials |